The objective of this study is to constitute cohorts of IBD versus non-IBD patients to identify (a) new biomarker(s) of intestinal dysbiosis associated with inflammatory bowel disease, and develop a prototype for assaying such marker(s) in blood.
Male or female ≥ 18 years old
Able to follow the instructions of the study
Having signed an informed consent
A confirmed diagnosis of IBD
Commercial Pharmaceutical probiotic administration within the previous month
Treatment with antibiotics (whatever the route of administration) within last 3 months
Non-remission Cancer or in remission for less than 6 months
Any contraindication to colonoscopy and/or biopsy, left to PI discretion